NCT05683964View on ClinicalTrials.gov

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 19, 2023

Primary Completion Date

September 1, 2025

Study Completion Date

February 1, 2026

Conditions
Prostate AdenocarcinomaProstate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
DRUG

Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]

per standard care

DIAGNOSTIC_TEST

Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan

Per standard care

Trial Locations (1)

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER